Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7981
Reference
Name
National Patient Safety Alert – Shortage of verteporfin 15mg powder for solution for injection
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
HEALTH BOARDS
NATIONAL PATIENT SAFETY ALERT
SHORTAGES
CANCER TREATMENT
RETINOPATHY
Description
Verteporfin is indicated for the treatment of adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or adults with subfoveal choroidal neovascularisation secondary to pathological myopia. Verteporfin is also used in the treatment of ocular cancer in specialist centres. Verteporfin is used off-label for the management of central serous retinopathy with photodynamic therapy. Verteporfin has been in short supply globally since late 2020 due to capacity constraints at the manufacturing site. The issue is not expected to resolve until the middle of 2024. Since 2021, verteporfin supply has been restricted for use in ocular cancer centres in the UK.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2023-09-28 00:00:00
Click to go back to homepage